Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $170K | — | $1.53M | $21.3M | $47.5M | $44.6M |
| Revenue growth | — | — | — | — | — | — | — | 1284.5% | 123.7% | -6.1% |
| Gross profit | — | — | — | — | — | — | $1.45M | $20.0M | — | — |
| Gross margin | — | — | — | — | — | — | 94.4% | 94.1% | — | — |
| Operating income | -$2.87M | -$6.95M | -$10.4M | -$13.0M | -$17.9M | -$17.2M | -$22.6M | -$12.8M | $2.57M | -$6.28M |
| Operating margin | — | — | — | — | -10520.6% | — | -1471.6% | -60.1% | 5.4% | -14.1% |
| Net income | -$2.79M | -$7.05M | -$9.89M | -$12.8M | -$18.1M | -$17.3M | -$23.7M | -$16.0M | -$436K | -$9.74M |
| Net margin | — | — | — | — | -10652.4% | — | -1544.9% | -75.5% | -0.9% | -21.8% |
| EPS (diluted) | -$0.22 | -$0.47 | -$0.52 | -$0.64 | -$0.76 | -$0.67 | -$0.90 | -$0.60 | -$0.02 | -$0.34 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$2.12M | -$3.64M | -$7.83M | -$9.06M | -$15.6M | -$14.2M | -$18.1M | -$17.1M | $27.0M | -$12.5M |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $3.93M | $28.3M | $22.8M | $13.7M | $30.3M | $21.1M | $23.8M | $13.3M | $26.6M | $36.8M |
| Total assets | $3.97M | $28.4M | $22.9M | $14.1M | $31.4M | $22.4M | $26.9M | $26.9M | $44.9M | $70.6M |
| Total liabilities | $402K | $1.64M | $1.64M | $2.27M | $2.35M | $6.64M | $29.5M | $38.5M | $50.8M | $35.1M |
| Long-term debt | — | — | — | — | — | — | $24.9M | $30.9M | $19.3M | — |
| Shareholders' equity | $3.57M | $26.8M | $21.3M | $11.9M | $29.1M | $15.8M | -$2.57M | -$11.6M | -$5.87M | $35.5M |
| Retained earnings | -$114M | -$121M | -$131M | -$144M | -$162M | -$179M | -$203M | -$219M | -$220M | -$229M |
| Shares (wtd avg diluted) | 12.8M | 15.0M | 18.9M | 19.9M | 23.7B | 26.0M | 26.3M | 26.6M | 27.3M | 28.6M |
Every figure is extracted from FENNEC PHARMACEUTICALS INC.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.